Highlights Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Real-time Estimate Cboe BZX Other stock markets 03:57:14 2024-05-15 pm EDT			5-day change	1st Jan Change
147.5 ^USD	-0.27%		-2.82%	-22.68%

May. 07	HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating	MT
May. 02	Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed	May. 02	MT
Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Posts Q1 Revenue $494.3M, vs. Street Est of $426.9M	May. 02	MT
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024	May. 02	CI
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia	Apr. 30	CI
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	Apr. 08	MT
Sector Update: Health Care	Apr. 08	MT
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint	Apr. 08	MT
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	Apr. 07	CI
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives	Mar. 05	CI
How long will this bullish phase last?	Feb. 26
North American Morning Briefing : Earnings Back in -2-	Feb. 20	DJ
Alnylam Pharmaceuticals' Shares Fall on Q4 Revenue Miss	Feb. 15	MT
Alnylam Pharmaceuticals Q4 Non-GAAP Loss Narrows, Revenue Rises	Feb. 15	MT
Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Posts Q4 Revenue $439.7M, vs. Street Est of $442.3M	Feb. 15	MT
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024	Feb. 15	CI
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Alnylam Pharmaceuticals Says Preliminary 2023 Net Product Revenue Increased	Jan. 08	MT
Blackstone explores sale of Anthos Therapeutics -sources	Dec. 04	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Highlights

Filters